Collegium Pharmaceutical, Inc.

Is Collegium Pharmaceutical, Inc. technically bullish or bearish?

As of October 31, 2025, Collegium Pharmaceutical, Inc. shows a bullish technical trend with strong daily moving averages and mixed signals from MACD and Dow Theory, having outperformed the S&P 500 recently but lagging over the past year and five years.

As of 31 October 2025, the technical trend for Collegium Pharmaceutical, Inc. has changed from mildly bullish to bullish. The daily moving averages are bullish, and both the weekly and monthly Bollinger Bands indicate bullish conditions. However, the MACD shows a mildly bearish stance on the weekly timeframe, while the monthly is bullish. The Dow Theory presents a mildly bullish view on the weekly but is mildly bearish on the monthly.<BR><BR>In terms of performance, Collegium has outperformed the S&P 500 in the past week (2.71% vs. 0.71%), the past month (3.32% vs. 1.92%), and year-to-date (24.82% vs. 16.30%), but lags behind over the past year (6.87% vs. 19.89%) and the past five years (91.74% vs. 109.18%). Overall, the current technical stance is bullish, with moderate strength indicated by mixed signals across different timeframes.

Is Collegium Pharmaceutical, Inc. overvalued or undervalued?

As of August 28, 2025, Collegium Pharmaceutical, Inc. is considered overvalued due to its lower P/E ratio of 15 compared to the peer average of 22.77, an EV to EBITDA ratio of 4.89 versus 5.28, and a Price to Book Value of 4.25, alongside a recent 1-year return of -6.76% that lags behind the S&P 500's 17.14%.

As of 28 August 2025, the valuation grade for Collegium Pharmaceutical, Inc. has moved from fair to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its P/E ratio of 15, which is significantly lower than its peer average P/E of approximately 22.77, and an EV to EBITDA ratio of 4.89 compared to the peer average of 5.28. Additionally, the Price to Book Value stands at 4.25, suggesting a premium over its book value relative to peers.<BR><BR>In comparison to its peers, Ligand Pharmaceuticals, Inc. has a notably high P/E ratio of -67.27, while Innoviva, Inc. shows an expensive valuation with a P/E of 16.41. Despite a strong return of 109.14% over the past three years, Collegium's recent performance has lagged behind the S&P 500, with a 1-year return of -6.76% compared to the S&P 500's 17.14%. This further supports the conclusion that Collegium Pharmaceutical, Inc. is currently overvalued.

How big is Collegium Pharmaceutical, Inc.?

As of Jun 18, Collegium Pharmaceutical, Inc. has a market capitalization of 971.56 million, with net sales of 664.29 million and a net profit of 43.91 million over the latest four quarters. The company's balance sheet shows shareholder's funds of 228.84 million and total assets of 1,663.59 million.

As of Jun 18, Collegium Pharmaceutical, Inc. has a market capitalization of 971.56 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 664.29 million for the latest four quarters and a net profit of 43.91 million during the same period.<BR><BR>As of Dec 24, the company's balance sheet shows shareholder's funds of 228.84 million and total assets of 1,663.59 million.

What does Collegium Pharmaceutical, Inc. do?

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing abuse-deterrent products for chronic pain treatment. As of March 2025, it reported net sales of $178 million and a market cap of approximately $971.56 million.

Overview: <BR>Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company engaged in developing and commercializing abuse-deterrent products for the treatment of chronic pain and other diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 178 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 971.56 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 15.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 3.17 <BR>Return on Equity: 28.03% <BR>Price to Book: 4.14<BR><BR>Contact Details: <BR>Address: 100 Technology Center Dr, STOUGHTON MA: 02072-4710 <BR>Tel: 1 781 7133699 <BR>Website: http://www.collegiumpharma.com/

Should I buy, sell or hold Collegium Pharmaceutical, Inc.?

Who are in the management team of Collegium Pharmaceutical, Inc.?

As of March 2022, the management team of Collegium Pharmaceutical, Inc. includes Chairman Michael Heffernan, CEO Joseph Ciaffoni, Lead Independent Director Gino Santini, and several independent directors: Rita Balice-Gordon, Garen Bohlin, John Fallon, and John Freund. They are responsible for the company's strategic direction and governance.

As of March 2022, the management team of Collegium Pharmaceutical, Inc. includes the following individuals:<BR><BR>- Mr. Michael Heffernan, Chairman of the Board<BR>- Mr. Joseph Ciaffoni, President, Chief Executive Officer, and Director<BR>- Mr. Gino Santini, Lead Independent Director<BR>- Dr. Rita Balice-Gordon, Director<BR>- Mr. Garen Bohlin, Independent Director<BR>- Dr. John Fallon, Independent Director<BR>- Dr. John Freund, Independent Director<BR><BR>These members play key roles in guiding the company's strategic direction and governance.